Skip to main content
. 2014 Dec 8;144(1):107–115. doi: 10.1111/imm.12355

Figure 2.

Figure 2

Effect of anti-FcεRI monoclonal antibody (mAb) on IgE-mediated biphasic increase in airway resistance at the fourth challenge. (a) Experimental protocol for treatment with anti- FcεRI mAb. Anti-FcεRI mAb was intraperitoneally administered twice a day on days –2, –1 and 0 [OE-1 (4th) + anti-FcεRI mAb]. Negative and positive controls were non-sensitized–challenged [NS-C (4th)] and OE-1-sensitized, hamster IgG-treated [OE-1 (4th) + hamster IgG] mice, respectively. (b) Effect of anti-FcεRI mAb on the increased levels of ovalbumin (OVA) -specific IgE and IgG1 in serum 24 hr after the fourth challenge (Day 9). (c) Effect of anti-FcεRI mAb on the biphasic increase in airway resistance after the fourth challenge. Each value is the mean ± SEM of three to five animals from one experiment. *P < 0·05 compared with OE-1 (4th) + rat IgG1 group.